Compare RLI & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLI | INDV |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | 1994 | 2014 |
| Metric | RLI | INDV |
|---|---|---|
| Price | $50.44 | $37.70 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $62.40 | N/A |
| AVG Volume (30 Days) | 933.8K | ★ 1.7M |
| Earning Date | 04-22-2026 | 06-08-2026 |
| Dividend Yield | ★ 5.16% | N/A |
| EPS Growth | 16.84 | ★ 8100.00 |
| EPS | 0.60 | ★ 0.69 |
| Revenue | ★ $1,882,448,000.00 | $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.53 | N/A |
| P/E Ratio | $83.47 | ★ $51.35 |
| Revenue Growth | ★ 6.33 | 4.29 |
| 52 Week Low | $47.26 | $13.42 |
| 52 Week High | $76.41 | $41.00 |
| Indicator | RLI | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 56.80 |
| Support Level | $47.26 | $35.36 |
| Resistance Level | $54.18 | $38.08 |
| Average True Range (ATR) | 1.41 | 1.40 |
| MACD | 0.11 | -0.35 |
| Stochastic Oscillator | 28.73 | 85.90 |
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety, and it derives a majority of its revenue from the Casualty segment.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).